| |
|
 |
 |
|
 |
|
 |
|
| |
|
|
|
|
Optimata, Developer of Predictive Biosimulation for Drug Development, Appoints Guy Malchi President
Optimata, Developer of Predictive Biosimulation for Drug Development, Appoints Guy Malchi President
Optimata Ltd., the developer of the revolutionary Virtual Cancer Patient and other innovative predictive biosimulation technologies, has appointed Guy Malchi as President.
Optimata's Virtual Patient Engines create in silico 'clones' for individual patients, enabling drug developers to conduct an unlimited number of “virtual trials” dynamically testing an almost infinite combination of dosages, treatment schedules and patient population characteristics.
"Guy's superb management experience in introducing new technologies to the biopharmaceutical industry will be a tremendous asset as we commercialize our technologies, initially for the cancer and hematology drug sectors," said Prof. Zvia Agur, Founder and Chairperson.
"Working with Optimata gives me an exciting opportunity to be part of a breakthrough computer-based approach to drug development and treatment, one that promises to dramatically reduce costs, " said Guy Malchi, President.
Malchi previously served as Founder and Head of Tefen Ltd.'s European Life Science Practice. Tefen is a leading international operations management consultancy specializing in design and implementation of performance improvement programmes. During Malchi's tenure the revenue of the company's life science sector grew by more than 400 percent. As he led the new client acquisition and business development processes in front of senior decision makers at leading Pharmaceutical, Biotech, and Medical Devices organisations.
Guy Malchi graduated with an Executive MBA from the London Business School and a B.Sc. in Industrial Engineering from Tel Aviv University.
About Optimata
Optimata is a developer of predictive biosimulation technologies known as the Virtual Patient Engine for use in drug development and in the individualization of therapeutic treatments.
For drug developers, Optimata offers a rational approach for the selection of patient populations and the optimization of drug scheduling and dosage. Optimata’s technologies significantly reduce the number of pre-clinical and clinical trials required, enabling trials to be performed only for decisive validations.
Optimata’s technology is based on a computer-generated method of accurately predicting how individual patients or patient populations respond to a compound. The technology combines computer models of human physiology, diseases and the therapeutic impact of a compound.
The technology enables drug developers to conduct an unlimited number of “virtual trials” to be carried out that result in a prediction of the dynamic interaction between an almost infinite combination of dosages, treatment schedules and patient population characteristics. Optimata has used its Virtual Patient Engine technology in optimization projects for Novartis, Rotterdam University, etc. The company currently is carrying out breast cancer clinical trials at Nottingham City Hospital in the UK at the Hadassah, Soroka and Meir Hospitals in Israel. Optimata was founded in 1999 by Prof. Zvia Agur, a world-renowned biomathematician who has pioneered methods of using computer modeling for optimizing treatment protocols in cancer and pathogenic diseases.
 |
| |